Competitor Analysis: Antibody-Drug Conjugates (ADC) 경쟁 분석 : 항체-약물 접합체(ADC)

종양을 표적으로 하는 항체와 암치료를 위한 약제의 접합체에 초점을 맞추어, 항체-약물 접합체 분야의 경쟁 동향, 각 기업의 연구개발 파이프라인 등을 분석하여 전해드립니다.

제1장 항체-약물 접합체(ADC)

• 항체-약물 접합체
• 면역 접합체

제2장 항체-약물 접합체(ADC)의 연구개발 파이프라인

• Abbott
• Aeterna Zentaris
• ALLOZYNE
• Alpha Cancer Technologies
• Ambrx
• Amgen
• Amunix
• Astellas Pharma Inc.
• Bayer Healthcare Pharmaceuticals
• Biotest
• Bristol-Myers Squibb (BMS)
• Celldex Therapeutics
• Centrose
• Cytoguide
• Daiichi-Sankyo
• Genmab
• GlaxoSmithKline (GSK)
• ImmunoGen
• Immunomedics
• Intellect Neurosciences
• Merrimack Pharmaceuticals
• Mersana Therapeutics
• Pfizer
• Progenics
• Roche
• Sanofi
• Seattle Genetics
• Synthon
• Tactic Pharma
• Takeda Pharmaceutical Company Limited.
• UCB
• Wilex

The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The emerging therapeutic class of antibody-drug conjugates (ADC) is coming of age. Two approved and marketed ADC drugs utilizing each one of the two major technologies (auristatin and maytansin derivatives) have paved the way for a total of further 33 ADCs in clinical studies and further six ADCs in IND enabling studies. Adcetris posted US sales of US$ 138 mln in 2012 and with the start of marketing of Kadcyla, sales of this therapeutic class are expected to reach blockbuster size. New linker and toxic payload technologies are being developed and the first representative ADCs from the new technologies are approaching clinical proof of concept testing.

The report includes a compilation of currently active projects in research and development of antibody-drug conjugates and other immunoconjugates in oncology. In addition, the report lists company-specific R&D pipelines of antibody-drug conjugates.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

La Merie Publishing is an independent business information provider for the biopharmaceutical industry. We publish reports and newsletters, and provide the service of preparing tailor-made reports.

The consultancy business of La Merie Business Intelligence was established in 2002 by Ulrich Martin, MD, based on his extensive experience in the biopharmaceutical industry both as a physician specializing in pharmacology and as a co-founder and CEO of a product development biotech company.

• Adcetris Pipeline
• Antibody-Drug Conjugates with Auristatin Derivatives
• Antibody-Drug Conjugates with Pyrrolobenzodiazepine (PBD) Derivatives
• Kadcyla Pipeline
• Antibody-Drug Conjugates with Maytansinoid Derivatives
• Antibody-Drug Conjugates with Irinotecan Derivatives
• Antibody-Drug Conjugates with Doxorubicin
• Antibody-Drug Conjugates with Calicheamicin Derivatives
• Antibody-Drug Conjugates with Duocarmycin Derivative
• Antibody-Drug Conjugates with Various Drugs
• Antibody-Drug Conjugates with Not Disclosed Drugs
• Other Immunoconjugates
• Antibody-Drug Conjugates: R&D Collaboration Agreements
• Antibody-Drug Conjugates: Licensing Agreements About La Merie
• Corporate ADC R&D Pipelines